4-1BB co-stimulation further enhances anti-PD-1-mediated reinvigoration of exhausted CD39
CD8-positive T-lymphocytes
adaptive immunity
immunity
lymphocytes
tumor-infiltrating
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
accepted:
24
11
2020
entrez:
18
12
2020
pubmed:
19
12
2020
medline:
21
9
2021
Statut:
ppublish
Résumé
Responses to immunotherapy vary between different cancer types and sites. Here, we aimed to investigate features of exhaustion and activation in tumor-infiltrating CD8 T cells at both the primary and metastatic sites in epithelial ovarian cancer. Tumor tissues and peripheral blood were obtained from 65 patients with ovarian cancer. From these samples, we isolated tumor-infiltrating lymphocytes (TILs) and peripheral blood mononuclear cells. These cells were used for immunophenotype using multicolor flow cytometry, gene expression profile using RNA sequencing and ex vivo functional restoration assays. We found that CD39 Severely exhausted PD-1
Sections du résumé
BACKGROUND
Responses to immunotherapy vary between different cancer types and sites. Here, we aimed to investigate features of exhaustion and activation in tumor-infiltrating CD8 T cells at both the primary and metastatic sites in epithelial ovarian cancer.
METHODS
Tumor tissues and peripheral blood were obtained from 65 patients with ovarian cancer. From these samples, we isolated tumor-infiltrating lymphocytes (TILs) and peripheral blood mononuclear cells. These cells were used for immunophenotype using multicolor flow cytometry, gene expression profile using RNA sequencing and ex vivo functional restoration assays.
RESULTS
We found that CD39
CONCLUSION
Severely exhausted PD-1
Identifiants
pubmed: 33335029
pii: jitc-2020-001650
doi: 10.1136/jitc-2020-001650
pmc: PMC7745695
pii:
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
TNFRSF9 protein, human
0
Tumor Necrosis Factor Receptor Superfamily, Member 9
0
Apyrase
EC 3.6.1.5
ENTPD1 protein, human
EC 3.6.1.5
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
EMBO J. 2015 Aug 4;34(15):2042-58
pubmed: 26139534
Cancer Res. 2019 Jun 15;79(12):3011-3027
pubmed: 31053634
Nat Med. 2019 Jan;25(1):89-94
pubmed: 30510250
J Thorac Dis. 2017 Jul;9(7):1903-1910
pubmed: 28839988
Clin Cancer Res. 2017 May 15;23(10):2491-2505
pubmed: 27827318
Nat Rev Clin Oncol. 2014 Nov;11(11):630-2
pubmed: 25311350
N Engl J Med. 2015 Jan 22;372(4):311-9
pubmed: 25482239
N Engl J Med. 2018 Jun 14;378(24):2288-2301
pubmed: 29863955
Nature. 2018 May;557(7706):575-579
pubmed: 29769722
N Engl J Med. 2016 Nov 10;375(19):1856-1867
pubmed: 27718784
Nat Immunol. 2011 Jun;12(6):492-9
pubmed: 21739672
Genes Dis. 2018 May 17;5(3):194-203
pubmed: 30320184
PLoS One. 2018 Feb 22;13(2):e0192227
pubmed: 29470536
N Engl J Med. 2012 Jun 28;366(26):2455-65
pubmed: 22658128
Clin Cancer Res. 2015 Feb 1;21(3):611-21
pubmed: 25472998
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
Nat Rev Immunol. 2013 Apr;13(4):227-42
pubmed: 23470321
Immunity. 2019 Nov 19;51(5):840-855.e5
pubmed: 31606264
Prostate. 2014 Oct;74(14):1452-61
pubmed: 25111810
Genome Biol. 2014;15(12):550
pubmed: 25516281
Am J Respir Crit Care Med. 2015 Feb 15;191(4):377-90
pubmed: 25369536
Cancer Immunol Immunother. 2018 Dec;67(12):1825-1832
pubmed: 30171269
Cancers (Basel). 2019 Aug 26;11(9):
pubmed: 31455033
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Immunity. 2019 Jan 15;50(1):195-211.e10
pubmed: 30635237
Clin Cancer Res. 2017 Apr 15;23(8):1929-1936
pubmed: 27756788
Cell. 2017 Aug 24;170(5):927-938.e20
pubmed: 28841418
Pathol Res Pract. 2019 Aug;215(8):152404
pubmed: 30962002
Nat Commun. 2018 Jul 13;9(1):2724
pubmed: 30006565
J Immunol Methods. 2009 Jan 1;340(1):11-24
pubmed: 18929568
J Immunother Cancer. 2014 May 14;2:14
pubmed: 24883190
Nat Immunol. 2016 Dec;17(12):1467-1478
pubmed: 27776108
Cancer Discov. 2018 Sep;8(9):1069-1086
pubmed: 30115704
Blood. 2018 Jan 4;131(1):49-57
pubmed: 29118009
Semin Oncol. 2015 Aug;42(4):640-55
pubmed: 26320067
Front Immunol. 2018 May 01;9:947
pubmed: 29770138
J Immunother Cancer. 2019 Nov 21;7(1):316
pubmed: 31752994
Trends Immunol. 2015 Apr;36(4):265-76
pubmed: 25797516
Immunity. 2007 Oct;27(4):670-84
pubmed: 17950003
J Clin Oncol. 2015 May 1;33(13):1430-7
pubmed: 25452452
J Transl Med. 2019 Mar 27;17(1):99
pubmed: 30917841
Immunity. 2018 Apr 17;48(4):812-830.e14
pubmed: 29628290
Immunity. 2016 May 17;44(5):1005-19
pubmed: 27192566
Clin Cancer Res. 2014 Apr 1;20(7):1891-9
pubmed: 24691640
J Exp Med. 2008 Mar 17;205(3):625-40
pubmed: 18316415
Curr Opin Immunol. 2015 Apr;33:93-100
pubmed: 25710852
BMC Cancer. 2015 Feb 26;15:85
pubmed: 25881093
Immunology. 2015 Sep;146(1):11-22
pubmed: 26076649
Nat Commun. 2018 Nov 15;9(1):4809
pubmed: 30442944
Mol Oncol. 2014 Feb;8(1):150-8
pubmed: 24220311
BMC Cancer. 2018 May 29;18(1):601
pubmed: 29843633
Lung Cancer. 2014 Oct;86(1):78-84
pubmed: 25130083
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Nat Med. 2018 Jul;24(7):994-1004
pubmed: 29892065
Nat Rev Drug Discov. 2018 Jul;17(7):509-527
pubmed: 29904196
Sci Transl Med. 2019 Jun 12;11(496):
pubmed: 31189721
Curr Opin Cell Biol. 2015 Dec;37:1-8
pubmed: 26342994
BMC Bioinformatics. 2013 Jan 16;14:7
pubmed: 23323831
Cancer Cell. 2015 Dec 14;28(6):690-714
pubmed: 26678337
J Pathol. 2013 Sep;231(1):21-34
pubmed: 23780408
Gynecol Oncol. 2017 Jun;145(3):420-425
pubmed: 28392127
Clin Cancer Res. 2014 Jan 1;20(1):44-55
pubmed: 24045181
Eur J Cancer. 2016 Jun;60:1-11
pubmed: 27038842
Cell. 2016 Sep 8;166(6):1500-1511.e9
pubmed: 27610572
J Clin Invest. 2015 Sep;125(9):3335-7
pubmed: 26325031
J Immunol. 2016 Jan 1;196(1):484-92
pubmed: 26608920
J Ovarian Res. 2019 Jan 4;12(1):1
pubmed: 30609934
Lancet Oncol. 2015 Mar;16(3):257-65
pubmed: 25704439
J Clin Oncol. 2015 Dec 1;33(34):4015-22
pubmed: 26351349